双特异性抗体用于治疗多发性骨髓瘤
Anup Joseph Devasia1, Ajai Chari2, Guido Lancman3
1Princess Margaret Cancer Centre, Toronto, ON, Canada.
Blood cancer journal
|September 12, 2024
概括
双特异性抗体为复发性多发性髓瘤提供了新的希望,吸引T细胞向癌细胞. 目前正在进行研究以克服耐药性并探索它们在新诊断的患者中的使用.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 多发性骨髓瘤的治疗环境正在迅速发展.
- 虽然像单克隆抗体,蛋白酶体抑制剂 (PI) 和免疫调节剂 (IMiD) 这样的前期疗法已经改善了结果,但在复发期间会出现挑战.
- 新型免疫疗法对于管理复发性疾病至关重要.
研究的目的:
- 审查双特异性抗体在复发多发性髓瘤中的作用.
- 要突出它们的作用机制,有效性和安全性.
- 讨论正在进行的研究和未来的方向,包括克服耐药性和在早期治疗环境中使用.
主要方法:
- 对多发性骨髓瘤中双特异性抗体的当前文献和临床试验数据的综述.
- 对双特异性抗体向策略的分析 (例如,BCMA,GPRC5D,FcRH5).
- 讨论抵抗机制和克服它们的策略.
主要成果:
- 双特异性抗体在重度预治疗多发性骨髓瘤患者中显示出深度和持久的反应.
- 这些药物提供了可预测的安全性和现成的可用性.
- 针对BCMA,GPRC5D和FcRH5等抗原显示出有希望的结果.
结论:
- 双特异性抗体是复发性多发性髓瘤的重要治疗选择.
- 目前正在进行的研究旨在解决抵抗机制,并在治疗算法中优化它们的序列.
- 这些药物也正在被研究为新诊断的患者的第一线治疗.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


